Since we are not sure whether the adverse reaction to anti-IL6R antibody treatment observed in our patient with the ZNF334 truncation mutation was due to allergic reaction or the decrease in serum IL-6 level, our findings that geldanamycin could reduce the cold-induced upregulation of TNF, NLRP3, but not IL-6 in ZNF334+/− cells suggest that the Hsp90 inhibitor could be a potential treatment option for the patient. This evidence concerns the gene HSP90AA1 and allergic disease.